Gene sequencing for lung cancer under-used in Europe
pharmaphorum
JULY 10, 2023
Gene sequencing for lung cancer under-used in Europe Phil.Taylor Mon, 10/07/2023 - 09:37 Bookmark this
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
pharmaphorum
JULY 10, 2023
Gene sequencing for lung cancer under-used in Europe Phil.Taylor Mon, 10/07/2023 - 09:37 Bookmark this
Pharmaceutical Technology
APRIL 15, 2024
Discover the groundbreaking gene therapy patent by Ginkgo BioWorks Inc for treating NPC1 using AAV vectors. Learn how this innovative approach offers hope for rare genetic disorders like Neimann-Pick Disease Type C.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioSpace
FEBRUARY 9, 2021
will make an investment of $900 million into the company to support its gene sequencing research. Shares of Pacific Biosciences soared more than 21% in premarket trading after it was announced SB Management, a subsidiary of SoftBank Group Corp.,
pharmaphorum
NOVEMBER 8, 2024
Wales has extended a scheme to harness the power of genomics to improve cancer care and prevention via an alliance with gene-sequencing giant Illumina.
Bio Pharma Dive
AUGUST 10, 2020
The test, developed by Guardant Health, combines next-generation sequencing with a cancer blood test.
BioPharma Reporter
JULY 11, 2023
A new genetic sequencing technology from Element Biosciences has helped researchers from the Translational Genomics Research Institute (TGen), part of the City of Hope, identify the likely genetic causes of disorders in six of nine children from Sonora, Mexico.
pharmaphorum
NOVEMBER 3, 2020
Ring Chromosome 20 Syndrome, or (R)20, is an ultra-rare form of epilepsy with a devastating impact – yet despite huge leaps forward in gene sequencing in recent years, diagnoses are going down instead of up. The post Ring 20: Could the rare disease get left behind by next-generation gene sequencing? appeared first on.
BioTech 365
NOVEMBER 23, 2020
Companion Diagnostics Markets, 2025 – Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing – ResearchAndMarkets.com Companion Diagnostics Markets, 2025 – Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing – ResearchAndMarkets.com (..)
BioTech 365
MAY 5, 2021
First of its kind SARS-CoV-2 detection by partial N gene sequencing now publicly available at CLIA Certified Milford Connecticut laboratory First of its kind SARS-CoV-2 detection by partial N gene sequencing now publicly available at CLIA Certified Milford Connecticut laboratory … Continue reading →
BioSpace
OCTOBER 11, 2023
The European Union is expected to order the gene sequencing giant to divest Grail in the coming days, according to multiple media reports citing unnamed sources familiar with the matter.
pharmaphorum
FEBRUARY 23, 2022
Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases. The post Takeda grows in gene therapies again with $2bn Code Bio deal appeared first on. Last October it signed a $3.6 billion-plus.
pharmaphorum
AUGUST 10, 2021
Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. — Brad Loncar (@bradloncar) August 9, 2021.
XTalks
DECEMBER 14, 2022
Expanding upon the CRISPR-Cas9 gene editing system, researchers at MIT have designed a new technique called PASTE gene editing that can cut out defective genes and replace them with new genes in a safer and more efficient way. The PASTE gene editing technique was recently published in Nature Biotechnology.
FDA Law Blog
OCTOBER 24, 2024
Rather, developers of diagnostic tests and, indeed of any product that relies on free access to gene sequence and other biomarker information, should pay also close attention, as PERA would overturn longstanding judicial precedent. By 2010, about 2000 isolated human genes had been patented in the U.S.
Scienmag
MAY 4, 2021
Credit: Elizabeth Cooke Next-generation gene sequencing (NGS) technologies –in which millions of DNA molecules are simultaneously but individually analyzed– theoretically provides researchers and clinicians the ability to noninvasively identify mutations in the blood stream.
BioSpace
AUGUST 24, 2021
The development of COVID-19 vaccines, which took only months from the initial gene sequencing to the time shots were in arms, was the biggest story of 2020 alongside the pandemic itself.
BioTech 365
DECEMBER 3, 2020
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Research team develops software that cuts time, cost from gene sequencing.A team of Johns Hopkins University researchers has developed a new software that could revolutionize how DNA … Continue reading →
BioTech 365
APRIL 20, 2021
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Algorithm maps gene expression in space.As we accumulate more and more gene-sequencing information, cell-type databases are growing in both size and complexity.
pharmaphorum
SEPTEMBER 14, 2022
SparingVision has raised €75 million in second-round funding that will be used to fund clinical trials of gene therapies for ocular diseases retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD). The post SparingVision raises €75m for eye disease gene therapies appeared first on.
Medical Xpress
FEBRUARY 1, 2023
Next-generation cancer strategies rely on next-generation gene sequencing (NGS), which paves the way for new techniques and tools to detect mutations and determine patient therapy.
Scienmag
JULY 6, 2021
New method yields 10 times more data, reduces gene sequencing costs by one third Researchers have devised a way to multiply by more than ten-fold the accessible details of gene activity in individual cells.
Roots Analysis
OCTOBER 16, 2023
DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence. There are some motifs, such as hairpin loops which hinder the usability of a gene.
pharmaphorum
MARCH 15, 2022
Gene sequencing specialist Illumina has started rolling out a new test that looks for a battery of tumour-associated genes from a single tissue sample, and could be used to help guide treatment for a broad range of cancers. The post Illumina debuts its multi-gene test for cancer in Europe appeared first on.
Scienmag
JUNE 1, 2022
New research led by scientists at the Milner Centre for Evolution at the University of Bath suggests that determining evolutionary trees of organisms by comparing anatomy rather than gene sequences is misleading.
pharmaphorum
JUNE 23, 2022
Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). It is also working with Eli Lilly on in vivo gene-editing drugs against three targets, including one in Duchenne muscular dystrophy, under the terms of a $1.4
BioTech 365
FEBRUARY 4, 2021
GenapSys), the company behind the world’s first highly accurate, affordable, and accessible gene sequencer, today announced it has named Jason Myers as its Chief Executive … Continue reading → GenapSys Names Jason Myers CEO GenapSys Names Jason Myers CEO REDWOOD CITY, Calif.–(BUSINESS
pharmaphorum
MARCH 10, 2022
Scenic’s platform technology Cell-Seq is used to seek out genetic modifiers, defined as gene sequences that counteract the effect of another disease-associated gene.
pharmaphorum
AUGUST 10, 2021
The three-year project – led by respiratory medicine expert Dr Timothy Hinks from the Oxford University Respiratory Medicine Unit – will use whole-genome sequencing of around 500 patients with severe asthma, comparing their gene sequences with control subjects who don’t have asthma.
Roots Analysis
FEBRUARY 21, 2022
Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.
pharmaphorum
APRIL 23, 2021
Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform. . Vertex is also offering up to $1.3 For example, adding a small-molecule might stabilise the medicine, allowing levels of the target protein to increase.
pharmaphorum
DECEMBER 14, 2022
The two partners have revealed the first clinical data from a phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – that are thought to be driving a patient’s cancer.
pharmaphorum
JANUARY 5, 2023
The data was from their phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – thought to be driving a patient’s cancer. The post Boost for mRNA as Moderna to acquire OriCiro for $85 million appeared first on.
pharmaphorum
FEBRUARY 22, 2021
Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. . million in Europe.
pharmaphorum
OCTOBER 12, 2022
The neoantigens are selected based on gene sequencing of either a tumour biopsy or a blood sample, with an individual vaccine tailored to the patient manufactured and administered in a matter of weeks.
pharmaphorum
AUGUST 21, 2020
Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing.
Roots Analysis
FEBRUARY 23, 2022
Next Generation Sequencing (NGS) Library Preparation Kits. Driven by the increasing demand for gene therapies and the introduction of novel and advanced NGS techniques, the market is poised to grow at a CAGR of 18%, during the time period 2021-2035. Likely Growth of the NGS Library Preparation Kits Market.
pharmaphorum
OCTOBER 1, 2021
Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards the £5 billion ($6.7 billion) mark.
The Pharma Data
DECEMBER 28, 2020
Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs.
pharmaphorum
MAY 18, 2021
The advantage of plant-based production is that it is quick – Medicago says it produced the main ingredient for its vaccine just 20 days after the gene sequence of SARS-CoV-2 was published – and is easily scalable simply by cultivating additional plants.
Pharmaceutical Technology
MAY 26, 2023
Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines. As per the company, dbDNA is suitable for rapid, scalable manufacture of GMP DNA and can incorporate gene sequences of sizes ranging from 500bp to 20kb, which are typically unstable as pDNA.
pharmaphorum
FEBRUARY 19, 2021
“Since 2020 there has been a 50% increase in sequences produced in African countries. This is a priority area for us to ensure that all African countries are equipped to carry out gene sequencing locally or can send samples to reference laboratories.”. Novavax has also signed a deal to provide 1.1
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content